Clinical Profile and Influences on Outcomes in Patients Hospitalized for Acute Pericarditis

Kytö, Ville; Sipilä, Jussi; Rautava, Päivi

doi:10.1161/circulationaha.114.010376

Cited by 178 publications

(119 citation statements)

References 33 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we observed a significant decline in the proportion of women hospitalized with acute pericarditis. This is consistent with recently reported findings from a Finnish acute pericarditis cohort study where 65% of patients were men and the incidence rate was 2.02 (95% CI 1.82-2.26; p < 0.001) times higher among men than women [14]. These sex-based differences could be related to the anti-inflammatory effects of estrogen and the proinflammatory role of testosterone in the pericardial and myocardial tissue.…”

Section: Discussionsupporting

confidence: 91%

“…The overall CFR of 1.8% in our study is comparable to that reported in previous studies [14]. The CFR declined by 33.4% during the study period.…”

Section: Discussionsupporting

confidence: 89%

“…Only 3 previous studies have reported population-based estimates of acute pericarditis incidence rates [14,17,18]. Imazio et al [18 ]studied all cases of incident acute pericarditis in a prospective cohort study in an urban area of 220,000 inhabitants and estimated the incidence pericarditis to be 27.7 per 100,000 person-years.…”

Section: Discussionmentioning

confidence: 99%

“…This estimate was slightly higher than in our study (5.7 per 100,000 person-years), maybe because that study was designed to capture hospitalized as well as nonhospitalized cases of pericarditis. Most recently, Kytö et al [14 ]estimated the incidence of acute pericarditis hospitalizations in Finland to be 3.32 per 100,000 person-years; this lower hospitalization rate may have been due to the exclusion of small regional hospitals in the study. In contrast to these previous studies, our estimates of the incidence of pericarditis hospitalizations are based on a weighted sample of national discharges that captured >90% of all hospitalizations in the USA.…”

Section: Discussionmentioning

confidence: 99%

“…Patients ≥16 years of age with a primary diagnosis of acute pericarditis were included using appropriate ICD-9 codes. We excluded all cases with a secondary diagnosis of post-MI syndrome, Dressler's syndrome and AMI using appropriate ICD-9 and CCS codes, similar to previous studies [14] (online suppl. table 1; for all online suppl.…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Acute Pericarditis-Associated Hospitalization in the USA: A Nationwide Analysis, 2003-2012

et al. 2016

View full text Add to dashboard Cite

Background and Objectives: Epidemiologic data on hospitalizations for acute pericarditis are scarce. We sought to study the trends in these hospitalizations and outcomes in the USA over a 10-year period. Methods: We used the 2003-2012 Nationwide Inpatient Sample database to identify admissions with a primary diagnosis of acute pericarditis. Outcomes included hospitalization rate, case fatality rate (CFR), length of stay (LOS), hospital charges, complications and diagnostic and therapeutic procedures. Results: We observed an estimated 135,710 hospitalizations for acute pericarditis among patients ≥16 years during the study period (mean age 53.5 ± 18.5 years; 40.5% women). The incidence of acute pericarditis hospitalizations was significantly higher for men than for women [incidence rate ratio (IRR) 1.56; 95% confidence interval (CI) 1.54-1.58; p < 0.001]; it decreased from 66 to 54 per million person-years (p < 0.001). CFR and LOS declined significantly during the study period (CFR: 2.2% in 2003 to 1.4% in 2012; LOS: 4.8 days in 2003 to 4.1 days in 2012; p < 0.001 for both). The average inflation-adjusted health-care charge increased from USD 31,242 to 38,947 (p < 0.001). Conclusion: The hospitalization rate, CFR and LOS associated with acute pericarditis have declined significantly in the US population. Average charges for acute pericarditis hospitalization have increased.

show abstract

Section: Discussionsupporting

confidence: 91%

“…The overall CFR of 1.8% in our study is comparable to that reported in previous studies [14]. The CFR declined by 33.4% during the study period.…”

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Acute Pericarditis-Associated Hospitalization in the USA: A Nationwide Analysis, 2003-2012

et al. 2016

View full text Add to dashboard Cite

show abstract

Evaluation and Treatment of Pericarditis

Imazio

Gaïta²,

LeWinter

2015

JAMA

347

250

View full text Add to dashboard Cite

show abstract

Variants at the Interleukin 1 Gene Locus and Pericarditis

Thorolfsdottir,

Jonsdottir,

Sveinbjornsson

et al. 2024

JAMA Cardiol

View full text Add to dashboard Cite

ImportanceRecurrent pericarditis is a treatment challenge and often a debilitating condition. Drugs inhibiting interleukin 1 cytokines are a promising new treatment option, but their use is based on scarce biological evidence and clinical trials of modest sizes, and the contributions of innate and adaptive immune processes to the pathophysiology are incompletely understood.ObjectiveTo use human genomics, transcriptomics, and proteomics to shed light on the pathogenesis of pericarditis.Design, Setting, and ParticipantsThis was a meta-analysis of genome-wide association studies of pericarditis from 5 countries. Associations were examined between the pericarditis-associated variants and pericarditis subtypes (including recurrent pericarditis) and secondary phenotypes. To explore mechanisms, associations with messenger RNA expression (cis-eQTL), plasma protein levels (pQTL), and CpG methylation of DNA (ASM-QTL) were assessed. Data from Iceland (deCODE genetics, 1983-2020), Denmark (Copenhagen Hospital Biobank/Danish Blood Donor Study, 1977-2022), the UK (UK Biobank, 1953-2021), the US (Intermountain, 1996-2022), and Finland (FinnGen, 1970-2022) were included. Data were analyzed from September 2022 to August 2023.ExposureGenotype.Main Outcomes and MeasuresPericarditis.ResultsIn this genome-wide association study of 4894 individuals with pericarditis (mean [SD] age at diagnosis, 51.4 [17.9] years, 2734 [67.6%] male, excluding the FinnGen cohort), associations were identified with 2 independent common intergenic variants at the interleukin 1 locus on chromosome 2q14. The lead variant was rs12992780 (T) (effect allele frequency [EAF], 31%-40%; odds ratio [OR], 0.83; 95% CI, 0.79-0.87; P = 6.67 × 10−16), downstream of IL1B and the secondary variant rs7575402 (A or T) (EAF, 45%-55%; adjusted OR, 0.89; 95% CI, 0.85-0.93; adjusted P = 9.6 × 10−8). The lead variant rs12992780 had a smaller odds ratio for recurrent pericarditis (0.76) than the acute form (0.86) (P for heterogeneity = .03) and rs7575402 was associated with CpG methylation overlapping binding sites of 4 transcription factors known to regulate interleukin 1 production: PU.1 (encoded by SPI1), STAT1, STAT3, and CCAAT/enhancer-binding protein β (encoded by CEBPB).Conclusions and RelevanceThis study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1–blocking drugs.

show abstract

Clinical Profile and Influences on Outcomes in Patients Hospitalized for Acute Pericarditis

Cited by 178 publications

References 33 publications

Acute Pericarditis-Associated Hospitalization in the USA: A Nationwide Analysis, 2003-2012

Acute Pericarditis-Associated Hospitalization in the USA: A Nationwide Analysis, 2003-2012

Evaluation and Treatment of Pericarditis

Variants at the Interleukin 1 Gene Locus and Pericarditis

Contact Info

Product

Resources

About